Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx further discuss Imagion’s progress in this recent interview with Boardroom Media.
Prestige Biopharma and Imagion Biosystems Sign an MOU, Developing Early Pancreatic Cancer Diagnosis Platform
August 11, 2023
SINGAPORE, and San Diego, California – Prestige Biopharma, a biopharmaceutical company specializing in innovative antibody therapies, with a strong dedication to tackling pancreatic cancer, and Imagion